Literature DB >> 23767969

Variability in clinical phenotypes of heterozygous and homozygous cases of Parkin-related Parkinson's disease.

Amanda J Thompson1, Sonja W Scholz, Andrew B Singleton, Angela Hardwick, Nikolaus R McFarland, Michael S Okun.   

Abstract

Parkin mutations are a common cause of early-onset Parkinson's disease. To study the clinical features and treatment responses of patients with homozygous or heterozygous Parkin mutations, we performed a retrospective chart review in six early-onset parkinsonism patients with pathogenic Parkin mutations. The clinical phenotypes observed in this cohort, all drawn from different families, were variable. All patients had a slowly progressive form of parkinsonism that responded well to dopaminergic therapy with the exception of one advanced case. Homozygous patients had an earlier age at disease onset than heterozygous patients. Two of our patients underwent bilateral deep brain stimulation (DBS) of the subthalamic nucleus or globus pallidus leading to a sustained positive response. Our observations support an earlier age of onset for homozygous cases and possible beneficial effects of DBS in Parkin-related parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23767969      PMCID: PMC4001762          DOI: 10.3109/00207454.2013.810626

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  7 in total

1.  Whatever the disease duration, stimulation of the subthalamic nucleus improves Parkin disease.

Authors:  Romain Lefaucheur; Stéphane Derrey; Lucie Guyant-Maréchal; Nathalie Chastan; David Maltête
Journal:  Parkinsonism Relat Disord       Date:  2010-05-20       Impact factor: 4.891

Review 2.  Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism.

Authors:  Anette Schrag; Jonathan M Schott
Journal:  Lancet Neurol       Date:  2006-04       Impact factor: 44.182

3.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.

Authors:  T Kitada; S Asakawa; N Hattori; H Matsumine; Y Yamamura; S Minoshima; M Yokochi; Y Mizuno; N Shimizu
Journal:  Nature       Date:  1998-04-09       Impact factor: 49.962

4.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.

Authors:  H Shimura; N Hattori; S i Kubo; Y Mizuno; S Asakawa; S Minoshima; N Shimizu; K Iwai; T Chiba; K Tanaka; T Suzuki
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

5.  Are parkin patients particularly suited for deep-brain stimulation?

Authors:  Ebba Lohmann; Marie-Laure Welter; Valérie Fraix; Paul Krack; Suzanne Lesage; Sophie Laine; Marie-Laure Tanguy; Jean-Luc Houeto; Valérie Mesnage; Pierre Pollak; Alexandra Durr; Yves Agid; Alexis Brice
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

6.  Parkin disease: a phenotypic study of a large case series.

Authors:  Naheed L Khan; Elizabeth Graham; Peter Critchley; Anette E Schrag; Nicholas W Wood; Andrew J Lees; Kailash P Bhatia; Niall Quinn
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

7.  Mutational analysis of parkin and PINK1 in multiple system atrophy.

Authors:  Janet A Brooks; Henry Houlden; Anna Melchers; Ansha J Islam; Jinhui Ding; Abi Li; Reema Paudel; Tamas Revesz; Janice L Holton; Nick Wood; Andrew Lees; Andrew B Singleton; Sonja W Scholz
Journal:  Neurobiol Aging       Date:  2010-01-19       Impact factor: 4.673

  7 in total
  2 in total

1.  Deep brain stimulation for monogenic Parkinson's disease: a systematic review.

Authors:  Tomi Kuusimäki; Jaana Korpela; Eero Pekkonen; Mika H Martikainen; Angelo Antonini; Valtteri Kaasinen
Journal:  J Neurol       Date:  2019-01-18       Impact factor: 4.849

Review 2.  Deep brain stimulation and genetic variability in Parkinson's disease: a review of the literature.

Authors:  Johanne Ligaard; Julia Sannæs; Lasse Pihlstrøm
Journal:  NPJ Parkinsons Dis       Date:  2019-09-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.